| __timestamp | AstraZeneca PLC | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 4050200000 |
| Thursday, January 1, 2015 | 4646000000 | 5047100000 |
| Friday, January 1, 2016 | 4126000000 | 6078400000 |
| Sunday, January 1, 2017 | 4318000000 | 6931500000 |
| Monday, January 1, 2018 | 4936000000 | 6861900000 |
| Tuesday, January 1, 2019 | 4921000000 | 7056300000 |
| Wednesday, January 1, 2020 | 5299000000 | 8149300000 |
| Friday, January 1, 2021 | 12437000000 | 12310800000 |
| Saturday, January 1, 2022 | 12391000000 | 9765700000 |
| Sunday, January 1, 2023 | 8040000000 | 8988300000 |
| Monday, January 1, 2024 | 10207000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. AstraZeneca PLC and Viatris Inc., two giants in the field, have shown intriguing trends in their cost of revenue from 2014 to 2023. AstraZeneca's cost of revenue peaked in 2021, reaching approximately 12.4 billion, a significant increase from its 2014 figure, reflecting a growth of over 110%. Meanwhile, Viatris Inc. also saw a substantial rise, with its cost of revenue nearly tripling from 2014 to 2021. However, both companies experienced a decline in 2023, with AstraZeneca's costs dropping by 35% from its peak, and Viatris Inc. seeing a 27% decrease. These shifts highlight the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions can significantly impact financial outcomes.
Johnson & Johnson vs Viatris Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down AstraZeneca PLC and Takeda Pharmaceutical Company Limited's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Regeneron Pharmaceuticals, Inc.'s Expenses
AstraZeneca PLC vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: AstraZeneca PLC and Galapagos NV
Cost of Revenue: Key Insights for Biogen Inc. and Viatris Inc.
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Perrigo Company plc
Cost Insights: Breaking Down Viatris Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Viatris Inc. vs Travere Therapeutics, Inc.